Dana-Farber Cancer Institute

https://www.dana-farber.org/

 

SGO 2023 Conference Coverage on VuMedi
B

SGO 2023 Phase 1 Trial of Botensilimab + Balstilimab in Patients With Recurrent Platinum Refractory/Resistant Ovarian Cancer

By SGO 2023 Conference Coverage on VuMedi FEATURING Bruno Bockorny
By SGO 2023 Conference Coverage on VuMedi FEATURING Bruno Bockorny
87 views
April 14, 2023
Comments 0
Login to view comments. Click here to Login

Featured Video

06:27
Johnson & Johnson

Challenges to Navigate in Locally Advanced or Metastatic EGFR+ NSCLC

Feat. M. Socinski, D. Waterhouse

Featured Video

11:12
Stemline

A proven CD123 targeted therapy for BPDCN

Feat. H. Erba
Gynecologic
07:23

SGO 2023 Phase 1 Trial of Botensilimab + Balstilimab in Patients Wit…

SGO 2023 Conference Coverage on VuMedi

B. Bockorny

87 views
33:45

Lynch Syndrome and Gynecologic Cancer Risk (and Risk Reduction)

Dana-Farber Cancer Institute

M. del Carmen

86 views